Ascendis Pharma A/S - Common Stock (ASND) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2015 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
ASND on Nasdaq
Shares outstanding
61,152,075
Price per share
$235.39
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
64,676,862
Total reported value
$13,780,935,511
% of total 13F portfolios
0.02%
Share change
+111,898
Value change
+$36,527,545
Number of holders
303
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Ascendis Pharma A/S - Common Stock (ASND) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WESTFIELD CAPITAL MANAGEMENT CO LP 8.5% -7.8% $1,115,183,925 -$73,663,872 5,185,696 -6.2% Westfield Capital Management Company, L.P. 31 Dec 2025
FMR LLC 8% $745,602,004 4,646,943 FMR LLC 31 Mar 2025
JANUS HENDERSON GROUP PLC 7.8% -2.5% $859,467,360 -$20,821,968 4,323,059 -2.4% JANUS HENDERSON GROUP PLC 30 Sep 2025
Artisan Partners Limited Partnership 5.2% $687,887,717 3,225,885 Artisan Partners Asset Management Inc. 31 Dec 2025
Capital International Investors 5.6% $548,747,120 3,109,225 Capital International Investors 30 Jun 2025
T. Rowe Price Investment Management, Inc. 4.8% -27% $530,338,200 -$182,106,580 2,667,563 -26% T. Rowe Price Investment Management, Inc. 30 Sep 2025

As of 31 Dec 2025, 303 institutional investors reported holding 64,676,862 shares of Ascendis Pharma A/S - Common Stock (ASND). This represents 106% of the company’s total 61,152,075 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Ascendis Pharma A/S - Common Stock (ASND) together control 86% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 17% 10,281,496 0% 23% $2,192,426,207
WESTFIELD CAPITAL MANAGEMENT CO LP 8.5% 5,185,696 -1.4% 4.6% $1,105,797,733
Avoro Capital Advisors LLC 8.4% 5,111,111 +0.02% 11% $1,089,893,310
FMR LLC 6.8% 4,153,311 -7.1% 0.05% $885,651,945
JANUS HENDERSON GROUP PLC 6.6% 4,061,641 -6% 0.39% $866,104,326
Artisan Partners Limited Partnership 5.3% 3,225,885 -13% 1.1% $687,887,701
Capital International Investors 5% 3,063,943 +0.11% 0.1% $653,355,205
FRANKLIN RESOURCES INC 3.1% 1,910,079 +20% 0.1% $407,305,320
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 3.1% 1,886,393 +0.19% 0.13% $402,254,443
WELLINGTON MANAGEMENT GROUP LLP 2.9% 1,762,721 -2% 0.07% $375,882,627
T. Rowe Price Investment Management, Inc. 2.7% 1,667,625 -37% 0.22% $355,605,000
PRICE T ROWE ASSOCIATES INC /MD/ 2.6% 1,570,260 -9% 0.04% $334,843,000
AMERICAN CENTURY COMPANIES INC 2.4% 1,443,141 +165% 0.15% $307,736,614
PERCEPTIVE ADVISORS LLC 1.8% 1,081,421 -0.65% 4.2% $230,602,214
PRINCIPAL FINANCIAL GROUP INC 1.7% 1,026,407 +29% 0.11% $218,871,029
BlackRock, Inc. 1% 628,200 +39% 0% $133,957,368
MORGAN STANLEY 1% 617,968 +52% 0.01% $131,775,763
GOLDMAN SACHS GROUP INC 0.98% 596,703 -8.6% 0.02% $127,240,947
Invesco Ltd. 0.96% 586,094 -36% 0.02% $124,978,684
AMERIPRISE FINANCIAL INC 0.9% 550,477 -2.2% 0.03% $117,383,715
CITADEL ADVISORS LLC 0.85% 519,516 +1780% 0.08% $110,781,591
JPMORGAN CHASE & CO 0.83% 507,240 +73% 0.01% $108,163,857
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 0.81% 496,837 0% 0.16% $105,946,000
FIL Ltd 0.78% 478,641 +4.2% 0.08% $102,065,407
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.77% 470,951 0.14% $100,425,591

Institutional Holders of Ascendis Pharma A/S - Common Stock (ASND) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 64,676,862 $13,780,935,511 +$36,527,545 $213.24 303
2025 Q3 63,798,487 $12,683,838,954 +$232,138,786 $198.81 279
2025 Q2 62,895,390 $10,855,906,781 -$373,773,069 $172.60 245
2025 Q1 65,180,066 $10,147,446,038 +$223,136,493 $155.86 241
2024 Q4 63,751,521 $8,776,308,689 +$115,863,512 $137.67 212
2024 Q3 62,595,716 $9,312,956,409 +$237,478,312 $149.31 218
2024 Q2 60,687,245 $8,276,478,215 -$25,623,552 $136.38 202
2024 Q1 60,791,422 $9,189,438,728 +$198,420,492 $151.17 188
2023 Q4 60,262,338 $7,590,188,894 -$95,295,592 $125.95 183
2023 Q3 60,279,508 $5,644,577,484 -$61,738,785 $93.64 157
2023 Q2 61,039,136 $5,447,708,812 -$42,606,636 $89.25 156
2023 Q1 60,982,797 $6,535,152,679 -$603,913,240 $107.22 160
2022 Q4 65,956,055 $8,054,269,679 -$66,421,048 $122.13 183
2022 Q3 66,716,414 $6,891,080,476 +$149,538,106 $103.26 177
2022 Q2 63,211,628 $5,875,622,934 +$99,259,708 $92.96 162
2022 Q1 61,928,932 $7,267,064,424 +$416,027,513 $117.36 169
2021 Q4 58,376,386 $7,851,336,290 -$60,447,865 $134.53 168
2021 Q3 58,008,737 $9,244,880,979 +$506,030,857 $159.39 162
2021 Q2 55,049,436 $7,239,726,130 +$277,622,452 $131.55 167
2021 Q1 52,687,197 $6,790,538,552 -$259,999,867 $128.88 172
2020 Q4 54,357,110 $9,065,494,890 +$123,538,090 $166.78 173
2020 Q3 53,548,292 $8,263,618,101 +$776,855,285 $154.32 150
2020 Q2 48,248,343 $7,132,005,530 +$39,025,561 $147.90 149
2020 Q1 47,871,754 $5,391,239,456 +$191,350,357 $112.61 143
2019 Q4 46,149,738 $6,420,287,137 -$13,680,500 $139.12 139
2019 Q3 46,122,563 $4,442,511,426 -$194,325,083 $96.32 127
2019 Q2 47,663,417 $5,487,484,115 +$237,283,765 $115.15 132
2019 Q1 45,989,019 $5,412,737,939 +$716,635,309 $117.70 137
2018 Q4 40,100,469 $2,509,199,237 -$10,826,186 $62.65 102
2018 Q3 40,188,306 $2,847,498,166 +$44,455,437 $70.86 94
2018 Q2 39,572,750 $2,632,379,192 +$96,237,781 $66.52 100
2018 Q1 38,126,373 $2,493,396,132 +$345,130,853 $65.40 89
2017 Q4 30,513,340 $1,222,363,447 +$50,139,269 $40.06 64
2017 Q3 28,774,674 $1,042,816,000 +$204,057,698 $36.25 59
2017 Q2 23,269,447 $646,000,000 +$80,276,736 $27.76 34
2017 Q1 20,898,775 $585,169,000 +$9,050,400 $28.00 34
2016 Q4 20,561,240 $416,160,000 +$130,784,664 $20.24 31
2016 Q3 13,995,656 $281,311,000 +$4,791,129 $20.10 22
2016 Q2 13,876,594 $184,147,000 +$10,182,326 $13.27 23
2016 Q1 12,036,579 $223,242,000 +$9,842,726 $18.55 25
2015 Q4 10,090,990 $184,865,000 +$7,675,460 $18.32 24
2015 Q3 8,925,979 $157,986,000 -$15,929 $17.70 24
2015 Q2 8,953,630 $157,820,000 +$7,731,541 $17.68 32
2015 Q1 8,477,992 $145,818,000 +$145,818,000 $17.35 35